Recombinant bispecific antibodies for cellular cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Bispecific antibodies target two antigens on different cells, aiming to recruit cytotoxic effector cells to tumor cells for cancer therapy.
• Early bispecific antibody trials faced challenges including low efficacy, Fc-mediated side effects, and immunogenicity, leading to reduced research interest.
• Advances in effector cell biology and antibody engineering have spurred a resurgence in bispecific antibody development for cancer treatment.

Purpose of the Study:

• To review the revival of bispecific antibodies in cellular cancer therapy.
• To highlight novel strategies and antibody engineering technologies improving bispecific antibody efficacy.
• To discuss the current clinical landscape of recombinant bispecific antibodies.

Main Methods:

• Review of existing literature on bispecific antibodies in cancer therapy.
• Analysis of advancements in effector cell biology and antibody engineering.
• Examination of in vitro and in vivo data for recombinant bispecific antibodies.

Main Results:

• Recombinant bispecific antibodies demonstrate improved efficacy in preclinical models.
• Novel engineering strategies address limitations of earlier bispecific antibody designs.
• The first recombinant bispecific antibody is in clinical trials for B-cell malignancies.

Conclusions:

• Bispecific antibodies represent a promising strategy for cellular cancer therapy, overcoming previous limitations through technological advancements.
• Ongoing research and clinical trials are validating the potential of engineered bispecific antibodies against various cancers, particularly B-cell malignancies.